Cytokine Inhibition in COPD Published by Dove Medical Press

Specific groups of COPD patients should be targeted with the specific anti-cytokine therapy if there is evidence of high expression of that cytokine, and there are features of the clinical expression of COPD that will respond.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

(PRWEB) April 30, 2014

International Journal of COPD has published the review “Cytokine inhibition in the treatment of COPD”.

As corresponding author Professor Chung says, “This review examines the importance of cytokines in many of the pathobiological processes of COPD and analyses the disease-modifying potential for these cytokines as targets for future treatments of COPD.”

Professor Chung continues, “Currently, there are no cytokine-targeted therapies, although there are increasing efforts to do so. The most promising candidates are discussed.”

As Dr Richard Russell, Editor-in-Chief, explains, “This is a very thorough review of the current knowledge base around cytokines in COPD. It will attract a wide audience from a multidisciplinary field.”

International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals.

Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine.


Contact

  • Angela Jones
    Dove Medical Press
    +649 443 3060 Ext: 207
    Email